Palbociclib (PD-0332991) HCl

Licensed by Pfizer 製品コードS1116

Palbociclib (PD-0332991) HCl化学構造

分子量(MW):483.99

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

サイズ 価格(税別)  
JPY 18260.00
JPY 28220.00
JPY 94620.00

カスタマーフィードバック(9)

  • PD-0332991 causes inhibition of proliferation of EAC cells in a dose-dependent manner. Western blots showing the phosphorylation status of pRB at Ser780 and Ser795 after incubation with 125 nmol/L PD-0332991 for 24 and 72 hours. Reduction in cyclin A expression and the expression of RB2 (p130) tumor suppressor 72 hours after PD-0332991 treatment are shown (bottom). Total pRB (RB1) and actin are loading controls and T293 cell lysate (293) is a positive control for total pRB and phospho-pRB (Ph-RB). E, anchorage-independent growth of the 3 cell lines in the presence or absence (Cnt) of 125 nmol/L PD-0332991 for 3 weeks.

    Clin Cancer Res 2011 17(13), 4513-22. Palbociclib (PD-0332991) HCl purchased from Selleck.

    b, c MelJuso cells were treated for 12–48 h with 1 µM Selumetinib or 5 µM Palbociclib and the cells were fixed, stained with propidium iodide and cell cycle distribution was determined by flow cytometry (b) and whole cell extracts were fractionated by SDS-PAGE, transferred onto PVDF membrane and immuno-blotted with the indicated antibodies (c). Data is from a single experiment representative of three separate experiments with similar results. The data in (b) are mean ± S.D. from a single experiment with three replicate dishes of cell per data point; similar results were obtained in two additional experiments

    Cell Mol Life Sci, 2016, 73(4):883-900. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • (A) Percentage of DN3a cells in S-phase (as gated on DAPI profile) from control (Zfp36l1/2fl/fl) and Zfp36l1/2fl/fl; CD2Cre (DCKO) mice, after 1 d of treatment with vector or palbociclib (drug).

    J Immunol, 2016, 197(7):2673-85. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Patient tumor cell sensitivity to combinatorial treatment with histone deacetylase (HDAC)/cyclin-dependent kinase (CDK) inhibitors in 3-D culture. The effect of each drug or drug combination was assessed by fluorescent dye to identify live (green) and dead cells (red). Cells from breast reduction patients were used as non-cancer control in the assay.

    Pharmacogenomics J 2013 13(1), 94-104. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • The expression of respective proteins in CDK4/6-Rb-apoptosis pathway in cells was examined by Western blot after 3 days of palbociclib treatment.

    Biochim Biophys Acta, 2018, 1864(5 Pt A):1573-1582. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Cdk4 is upregulated in ARMS and mMSCs transfected with PAX7-FKHR fusion gene (MP7F), and can be specifi cally inhibited. D: IF results showing overexpression of cdk4 in MP7F cells compared to parental mMSCs and reduced expression of cdk4 after treatment of MP7F cells with the cdk4 inhibitor, PD-0332991. E: IF results showing MyoD1 expression in parental mMSCs cells, and MP7F cells untreated and after treatment with the cdk4 inhibitor, PD-0332991.

    Clin Transl Oncol 2012 14(3), 197-206 . Palbociclib (PD-0332991) HCl purchased from Selleck.

  • WM3734 melanoma cells were treated by PD-0332991 for 36 hours; melanoma cells treated by Doxorubicin (DXR)  at 0.5 μM is included as a control.

     

     

    Dr. Gao Zhang of University of Pennsylvania. Palbociclib (PD-0332991) HCl purchased from Selleck.

    Serum-deprived T98G glioma cells are restimulated with serum(FBS) with or without 1 μΜ PD-0332991.

     

     

    Dr. Sabine Paternot and Dr Pierre Roger of IRIBHM, ULB, Brussels. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • P16INK4A knockdown in INK4A/ARF-wt human glioma cell LN319 potentiates PDGF-Apromoted anchorage-dependent growth in vitro. Soft agar growth of Ink4a/Arf-deficient mAst and LN444 cells treated with PD0332991. (A) IB analysis. (B) Quantification of soft agar assays. β-actin was used as a loading control in all IB experiments. Data are presented as mean ± s.d. and representative of two independent experiments. **, P < 0.01; ***, P < 0.001

    Dr. Kun-Wei Liu from University of Pittsburgh. Palbociclib (PD-0332991) HCl purchased from Selleck.

製品安全説明書

CDK阻害剤の選択性比較

生物活性

製品説明 Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.
特性 Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
ターゲット
CDK4/CyclinD3 [1]
(Cell-free assay)
CDK4/CyclinD1 [1]
(Cell-free assay)
CDK6/CyclinD2 [1]
(Cell-free assay)
9 nM 11 nM 15 nM
体外試験

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser780. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. [1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. [2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. [3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLM13 M4XCbmtqdmG|ZTDBd5NigQ>? MVeyOEBp NXz1R4xUUW6qaXLpeIlwdiCxZjDDSGs1KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhWmJicHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlAxOiEQvF2= M4PVOlI1PjRzMUCz
COLO205 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\oU|czKGh? MnTSRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{\XO|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjB|NjFOwG0> NUGw[XJQOjR4NEGxNFM>
U937 M3nlV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mne2O|IhcA>? MnGwRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{\XO|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjF2IN88US=> Mny2NlQ3PDFzMEO=
MOLM13 MkHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3K2SFczKGh? M4X4UWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTV;MUVE{KGOnbHzzJIhiemKxcnnu[{BHVFR|IFnUSEBufXSjboSgZZN{\XO|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjB7NjFOwG0> NVzES4pwOjR4NEGxNFM>
MOLM13 M4\PcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTlO|IhcA>? MnfaRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDzc5Ji\mWwaXKtdoV{cXO2YX70JIh2dWGwIF3PUG0yOyClZXzsd{Bie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMEm2JO69VQ>? MVmyOFY1OTFyMx?=
MDA-MB-435 NITieXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXlTZUzPCCq NXnoOnJQUUN3ME2wMlE3KM7:TR?= NIfYNFIyPThyMUizNS=>
K562 NUfOZlBnS3m2b4TvfIlkKEG|c3H5 NX\xPYRPQTZiaB?= M4LLfGROW09? NYP6RXYyUUN3ME2yJO69VQ>? MWSyOFQyPzV4Nh?=
DU145 MmXHR5l1d3SxeHnjJGF{e2G7 MWS5OkBp MYjEUXNQ MYrJR|UxRTdwNTFOwG0> MVGyOFQyPzV4Nh?=
MDA-MB-231 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\nZ3EyKM7:TR?= NHPoUXQzPCCq MXzEUXNQ NUHNXGZ6S2WubDDjfYNt\SCjcoLld5Qh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEdzIIDoZZNm NWrFTIFkOjR2MUe1OlY>
MCF7 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHaPXg1OSEQvF2= NVzuXIRiOjRiaB?= NHHzfnFFVVOR Mme5R4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JGcyKHCqYYPl M2TaNlI1PDF5NU[2
MCF7 M3XTc2tqdmG|ZTDBd5NigQ>? M4riPVUh|ryP M3\3UVI1KGh? NXvLd|dUTE2VTx?= M4DKN2lvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgR2RMPC:leXPsbY5FOSCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHKndHnuc4Jt[XO2b33hJJBpd3OyaH;yfYxifGmxbjDheEBU\XJ5OEC= NHHBTVkzPDRzN{W2Oi=>
MDA-MB-231 M{flNWtqdmG|ZTDBd5NigQ>? NX7jbmFrPSEQvF2= NIroR2kzPCCq MWjEUXNQ NVHJVVNwUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBETEt2L3P5Z4xqdkRzIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZicnX0bY5w[myjc4TvcYEheGixc4Doc5J6dGG2aX;uJIF1KFOncke4NC=> NVPNNIt[OjR2MUe1OlY>
MDA-MB-231 M1LTN2Z2dmO2aX;uJGF{e2G7 MnjPNU0yOCEQvF2= MY[yOEBp MUPEUXNQ NGfa[WJld2W|IH7veEBqdmS3Y3WgZZBweHSxc3nzJIF{e2W|c3XkJIF{KFCDUmCgZ4xm[X[jZ3W= NFvDeIkzPDRzN{W2Oi=>
MCF7 NH7t[2RHfW6ldHnvckBCe3OjeR?= M2jJblEuOTBizszN NX\ucW9mOjRiaB?= M1y2XGROW09? Mn3o[I9meyCwb4SgbY5lfWOnIHHwc5B1d3OrczDhd5Nme3OnZDDhd{BRSVKSIHPs[YF3[Wen M{XOZ|I1PDF5NU[2
MDA-MB-231 MWnGeY5kfGmxbjDBd5NigQ>? NHXGUVUxNjVvMTFOwG0> M2TQPFQ5KGh? MkDDSG1UVw>? MYfoZZMhdm9iQ3XscEBkgWOuZTDhdpJme3RiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IIP1Zk1IOSCyaHHz[S=> MV6yOFQyPzV4Nh?=
MCF7 MW\GeY5kfGmxbjDBd5NigQ>? NGWwSYsxNjVvMTFOwG0> NWDqWm54PDhiaB?= MYjEUXNQ M4S3[ohieyCwbzDD[YxtKGO7Y3zlJIFzemW|dDDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgd5VjNUdzIIDoZZNm M2DOTlI1PDF5NU[2
697 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHJTWM2OD1zNEiuN|ghdk1? MYXTRW5ITVJ?
P12-ICHIKAWA Mo\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH23OIVKSzVyPUm2MlA1KG6P NFnpWmFUSU6JRWK=
NB69 M1m2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUP0NWVzUUN3ME2xOlEvQCCwTR?= M4jh[nNCVkeHUh?=
EoL-1 MoTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvTbnpKSzVyPUG4O{4zPiCwTR?= NVzZeYhHW0GQR1XS
BHT-101 NFf3Z3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M320ZmlEPTB;MUm4MlI2KG6P NIfOPXRUSU6JRWK=
SK-NEP-1 MmPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfJ[IpiUUN3ME2yNlAvODJibl2= NHrGT|lUSU6JRWK=
MHH-NB-11 NEX3[HVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnLRYxMUUN3ME2yNlAvOTlibl2= NUDVe5NSW0GQR1XS
AsPC-1 NUD0O25CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTJ3Mj61N{BvVQ>? MkPQV2FPT0WU
ES1 NGO0cYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7uV2VxUUN3ME2yOVYvOjVibl2= Mn3jV2FPT0WU
LAMA-84 M1TMTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFH3fpJKSzVyPUK1PE4yQSCwTR?= MmXVV2FPT0WU
MOLT-16 NFG4ZZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTaOWxKSzVyPUK1PE41QSCwTR?= NYTMZVR{W0GQR1XS
ES7 Mmf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTJ5Mz6wPUBvVQ>? M1PnUHNCVkeHUh?=
KY821 NYKybGpzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nCeGlEPTB;M{G0MlEhdk1? MWPTRW5ITVJ?
RT-112 NXXtUZduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTxXJBKSzVyPUOyNU4xPSCwTR?= MlvHV2FPT0WU
HL-60 M1rrN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIG0[5RKSzVyPUO0NE43PiCwTR?= M37acnNCVkeHUh?=
MOLT-4 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{OwZ2lEPTB;M{S1MlE{KG6P M4rXOnNCVkeHUh?=
KARPAS-45 NEH5UGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTN5Nj6xOkBvVQ>? NFTHdlNUSU6JRWK=
SK-N-AS MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELxXZRKSzVyPUO4O{45OyCwTR?= MkTWV2FPT0WU
CTB-1 M{G5SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2C3T2lEPTB;NEC1MlAzKG6P M{DBe3NCVkeHUh?=
NKM-1 MkDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLoUYhnUUN3ME20NVEvQDlibl2= MUTTRW5ITVJ?
HTC-C3 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVe4XZdKUUN3ME20N|IvQTVibl2= M4DtZ3NCVkeHUh?=
BE-13 NUD5TJBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTR2ND6yO{BvVQ>? MYnTRW5ITVJ?
KOSC-2 NEnoe2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLpOmhyUUN3ME20OlYvQSCwTR?= NG\uVFhUSU6JRWK=
NB14 M3rufWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\zd2lEPTB;NEizMlU5KG6P NULCRVdDW0GQR1XS
CAL-27 NX\1e5N7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fhO2lEPTB;NEm0MlU6KG6P MXzTRW5ITVJ?
H9 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVniO3ZRUUN3ME20PVUvPDNibl2= MknpV2FPT0WU
RS4-11 NXHxXGhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfQTWM2OD13MESuO|Mhdk1? NX2zbItwW0GQR1XS
PA-1 M2fad2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPzTWM2OD13MEmuPFYhdk1? NEftPHNUSU6JRWK=
MV-4-11 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTVzMz64OUBvVQ>? MULTRW5ITVJ?
OS-RC-2 M{f2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTV{MT62NkBvVQ>? NFnMOIpUSU6JRWK=
RPMI-8226 NYrj[oh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULmWIZnUUN3ME21NlYvQDZibl2= M4P0NHNCVkeHUh?=
HGC-27 NEfYcWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nWbGlEPTB;NU[0Mlk6KG6P NHrWNJpUSU6JRWK=
CHP-212 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUf6bWpjUUN3ME21PVMvPTlibl2= NXL3OndtW0GQR1XS
NB10 NYO2cVF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHLfFFPUUN3ME21PVkvOThibl2= NFr6bWJUSU6JRWK=
HH M4nJb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfBToNzUUN3ME21PVkvPDNibl2= NIjCc5pUSU6JRWK=
EW-16 NXvycWhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHMfIFKSzVyPU[wN{42OiCwTR?= NWXmdWxXW0GQR1XS
ES8 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWG4dFR4UUN3ME22NFUvOjFibl2= MmnXV2FPT0WU
HAL-01 NV3R[4Y4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XvdWlEPTB;NkC1MlY4KG6P M1;r[3NCVkeHUh?=
A204 NFjVS45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfnc2pKSzVyPU[zN{46OSCwTR?= M1P1UnNCVkeHUh?=
MHH-PREB-1 NHzYd2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjhRYxrUUN3ME22N|YvQTlibl2= MX7TRW5ITVJ?
EM-2 NWfvUYFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTZ3MD62OEBvVQ>? NYD1T4FpW0GQR1XS
BV-173 NHTzZoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDqTWM2OD14NUKuOFghdk1? M1fOcHNCVkeHUh?=
ONS-76 NULzNWRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3qyN2lEPTB;Nke3MlgzKG6P MWPTRW5ITVJ?
KM-H2 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjKVplJUUN3ME22PVUvPTRibl2= NVHHfWc{W0GQR1XS
D-263MG MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVy4O4wzUUN3ME23NVcvOTJibl2= M1S2N3NCVkeHUh?=
ES3 M3rTPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHL5XVRKSzVyPUeyPE46OyCwTR?= MlLJV2FPT0WU
VA-ES-BJ NYLSVpY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DKU2lEPTB;N{OyMlI4KG6P M1TxXHNCVkeHUh?=
NBsusSR MnrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTd2Mj65PUBvVQ>? NXT1WGN5W0GQR1XS
NCI-H520 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTd2Nj61NkBvVQ>? MXjTRW5ITVJ?
ES5 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4WxcWlEPTB;N{WyMlghdk1? MnToV2FPT0WU
T-24 MmW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXrVlVZUUN3ME23O|gvPzFibl2= NX3wTnRrW0GQR1XS
SW962 MorNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\WTWM2OD16MEiuOlMhdk1? MYPTRW5ITVJ?
EW-3 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV71[mprUUN3ME24NFgvPzZibl2= M{\lTnNCVkeHUh?=
RXF393 MkLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLnTWM2OD16MUKuO|khdk1? MkSzV2FPT0WU
U251 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnizTWM2OD16MUOuPFghdk1? NHPWdIRUSU6JRWK=
CAMA-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTh|Mz65OEBvVQ>? M3TVVHNCVkeHUh?=
JVM-3 NVTZXWZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIqzTYNKSzVyPUi1NU44QCCwTR?= NHf1U5FUSU6JRWK=
COLO-800 NYqxRYc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrFWHdUUUN3ME24PVcvPzhibl2= NFvLSYZUSU6JRWK=
OVCAR-5 M{K1cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYf3O|dYUUN3ME25NFAvOSCwTR?= NHz5NHdUSU6JRWK=
LB1047-RCC MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTl{Nz61OkBvVQ>? MoTrV2FPT0WU
SW954 NIXrOWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjIdpFSUUN3ME25NlkvPDFibl2= M4rNV3NCVkeHUh?=
J-RT3-T3-5 M{nxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvXb3VKSzVyPUmzOk4xPiCwTR?= MkDJV2FPT0WU
Mewo MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkewTWM2OD17M{[uOkBvVQ>? MnnRV2FPT0WU
NCI-H1770 MlTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1K4VGlEPTB;OUSwMlU2KG6P MXzTRW5ITVJ?
HO-1-N-1 NFLMRo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\FSodEUUN3ME25OlIvQDFibl2= MoTMV2FPT0WU
HSC-3 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTl4Nj60PEBvVQ>? MXjTRW5ITVJ?
TYK-nu M{XQW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFv4PXZKSzVyPUm5PE4zPSCwTR?= MWHTRW5ITVJ?
KYSE-150 NWnLVo1lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTFwMECwO|Yh|ryP MVXTRW5ITVJ?
SN12C NVXoVoozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXKfXc4UUN3ME2xMlAxQDd3IN88US=> NHHGbpRUSU6JRWK=
MOLT-13 M1jwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWruTVRXUUN3ME2xMlAyPDJzIN88US=> MnTHV2FPT0WU
TE-11 NIW4PZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjlTWM2OD1zLkC0PFEzKM7:TR?= NGXuRYtUSU6JRWK=
DB M4Hwcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnJc5FKSzVyPUGuNFczPzNizszN NFXqN2RUSU6JRWK=
CAL-39 MnPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTFwMEe1NlIh|ryP MVrTRW5ITVJ?
A3-KAW M4TqWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrlRYhKSzVyPUGuNFg1ODhizszN Mn72V2FPT0WU
CHP-134 M323bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjCWGlKSzVyPUGuNVE5ODdizszN MoTuV2FPT0WU
TGW M1SyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTFwMUKzPVUh|ryP NYrjPJE5W0GQR1XS
QIMR-WIL NXj0VWkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnNR3k6UUN3ME2xMlE{OTN2IN88US=> NWK1XHl3W0GQR1XS
NCI-SNU-1 Mm\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;oOFhwUUN3ME2xMlE3OzV2IN88US=> NHvqXWlUSU6JRWK=
CGTH-W-1 M4HFfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWqxendOUUN3ME2xMlE4OTh4IN88US=> MkDFV2FPT0WU
MHH-ES-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTFwMUe5PFYh|ryP MlPlV2FPT0WU
LB2241-RCC MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTFwMUi2NkDPxE1? MUXTRW5ITVJ?
ML-2 NUfvTpV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTFwMkC3N|Qh|ryP NF;yU5pUSU6JRWK=
COR-L23 NHz4T21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnoTWM2OD1zLkKyPVM{KM7:TR?= NHnnSJZUSU6JRWK=
BFTC-905 NVy5doRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\BZoIyUUN3ME2xMlI1OjZ5IN88US=> M1\o[XNCVkeHUh?=
Hs-578-T NUHW[GJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfKUW54UUN3ME2xMlI2QDF5IN88US=> MkPnV2FPT0WU
KG-1 NHvaSpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHm3O|lKSzVyPUGuNlY3QDZizszN NF7LUJdUSU6JRWK=
HEL MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPPTWM2OD1zLkK5N|M5KM7:TR?= MlzsV2FPT0WU
A549 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTFwMkmzPVkh|ryP M3TtTnNCVkeHUh?=
COLO-741 Mme4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvsPXpKSzVyPUGuN|IxQDlizszN MXnTRW5ITVJ?
PC-3 NHP1V2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTFwM{WyNlEh|ryP M4O2bHNCVkeHUh?=
HOS MonrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTFwM{WyPVYh|ryP NI\WfGlUSU6JRWK=
HT-1080 NYG3RpAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1v3VmlEPTB;MT6zO|UyQSEQvF2= NUn3U|h5W0GQR1XS
TE-8 Mlr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PueGlEPTB;MT60NVc4PCEQvF2= M3jEPXNCVkeHUh?=
BHY NIf6cGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTOTWM2OD1zLkS2PVI{KM7:TR?= NGmxXWdUSU6JRWK=
BB65-RCC NHTIfmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEP1TlFKSzVyPUGuOVA2OjhizszN MnPQV2FPT0WU
HN MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mon0TWM2OD1zLkW0NFcyKM7:TR?= NFewZlVUSU6JRWK=
NCI-H441 NEHXV2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjNbnp{UUN3ME2xMlU1QTB5IN88US=> MnjaV2FPT0WU
RPMI-8866 MlS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvoSGNYUUN3ME2xMlU5PTB5IN88US=> NFXBWZVUSU6JRWK=
CAL-62 NYnofodsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7OTWM2OD1zLk[wPFYzKM7:TR?= MYPTRW5ITVJ?
MG-63 NVnoe3I{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHP2SXdKSzVyPUGuOlE5OTNizszN NHG4XW5USU6JRWK=
SK-LU-1 M{XvbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLUTWM2OD1zLk[yNVUzKM7:TR?= NGrsXmhUSU6JRWK=
BCPAP M3nwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXVUHBDUUN3ME2xMlY3PDV5IN88US=> NGi3WWRUSU6JRWK=
22RV1 MmfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mni0TWM2OD1zLk[3PFQ{KM7:TR?= NWLvSmdIW0GQR1XS
T47D NYfBO2V7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTFwNkiwOlEh|ryP NX;T[IdoW0GQR1XS
MSTO-211H NVnKepN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzSWoxKSzVyPUGuOlk3ODNizszN MmXnV2FPT0WU
DEL MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTFwN{CyO|Mh|ryP MXXTRW5ITVJ?
H4 NGnyV5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTFwN{OyNVIh|ryP M13iUnNCVkeHUh?=
CAL-51 NI[xdJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrqNIxKSzVyPUGuO|Q5PTVizszN MmTJV2FPT0WU
ABC-1 MoD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfsV5RKSzVyPUGuO|g2QDJizszN MVLTRW5ITVJ?
MZ2-MEL NEWzN3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjLcmxKSzVyPUGuO|k2PDJizszN M2H4WXNCVkeHUh?=
YKG-1 NX7xW3hpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfITWM2OD1zLkixNFYyKM7:TR?= NGe4UmtUSU6JRWK=
KM12 NYTCUoNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2P4Z2lEPTB;MT64NVYxOiEQvF2= MmLYV2FPT0WU
L-363 MlzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlyyTWM2OD1zLki3OFEzKM7:TR?= NVzxTHJ5W0GQR1XS
KU812 NIjt[pFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTFwOEmyPFIh|ryP Ml7rV2FPT0WU
LOXIMVI MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTFwOUGyNlgh|ryP NY\ye2N{W0GQR1XS
G-401 NV7tZnM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\hUZBEUUN3ME2xMlkzPDJ6IN88US=> NIeze2dUSU6JRWK=
SW780 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPaTWM2OD1zLkm2NlQ3KM7:TR?= MYDTRW5ITVJ?
SW872 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjoXHNOUUN3ME2xMlk5OzNizszN Ml;NV2FPT0WU
NB7 NEHkc5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17I[2lEPTB;MT65PVMzOyEQvF2= MWnTRW5ITVJ?
T98G MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTJwMEC2OlYh|ryP MmDLV2FPT0WU
SW1710 MnX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfiTWM2OD1{LkC2PVQ2KM7:TR?= NHnzcZlUSU6JRWK=
NCI-H1573 NHvtV5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjRV5dKSzVyPUKuNFczQThizszN M2jzWXNCVkeHUh?=
KE-37 NHv0[opIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjve5ExUUN3ME2yMlA5QTVzIN88US=> MXXTRW5ITVJ?
786-0 Mmq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHKTWM2OD1{LkG1OFM6KM7:TR?= MlfwV2FPT0WU
SAS Ml;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknnTWM2OD1{LkKwN|c1KM7:TR?= MlLDV2FPT0WU
CAL-54 NEXWbldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTJwMkC0NVMh|ryP NFjncG1USU6JRWK=
SF268 Mmi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3vTWM2OD1{LkKzNVIzKM7:TR?= NIC1TVBUSU6JRWK=
SW620 NFTnbHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDsemY6UUN3ME2yMlI3OTZ7IN88US=> NYD3eXR2W0GQR1XS
MN-60 NXLWPIZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHEbXRKSzVyPUKuN|ExPiEQvF2= NVLQSmltW0GQR1XS
EFO-27 MmHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTJwM{KwOVgh|ryP MluxV2FPT0WU
NCI-H747 MmrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrWZmVKSzVyPUKuN|IyQTlizszN MljPV2FPT0WU
HCC2218 M3T1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LsWGlEPTB;Mj6zOVM4PCEQvF2= NWexPFNZW0GQR1XS
MIA-PaCa-2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTJwM{[0N|ch|ryP MYDTRW5ITVJ?
SJSA-1 M{TpXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljRTWM2OD1{LkO3O|k3KM7:TR?= NWmwW4M4W0GQR1XS
RKO M3vkTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPpN5RKSzVyPUKuN|g1QTZizszN NYjxV|N1W0GQR1XS
NB6 M2fQbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGm1OHhKSzVyPUKuOFA{PzRizszN NYTBXnNGW0GQR1XS
ES4 NHHLVXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nDc2lEPTB;Mj60OVQzOiEQvF2= Moe3V2FPT0WU
EGI-1 Mke3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{n0b2lEPTB;Mj60Olg5OyEQvF2= MXjTRW5ITVJ?
CTV-1 MmfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rSb2lEPTB;Mj61Nlc4OyEQvF2= Mo\WV2FPT0WU
NCI-H1355 M2qwb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWS3b3VJUUN3ME2yMlU2QTVzIN88US=> Mk\kV2FPT0WU
GT3TKB NGnONY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTJwNUmxPVkh|ryP MkfZV2FPT0WU
SK-HEP-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LIe2lEPTB;Mj61PVI3PiEQvF2= MkTkV2FPT0WU
GAMG NGDBdo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFG5OHdKSzVyPUKuOVk{QTRizszN NIjidppUSU6JRWK=
SK-MES-1 M1;ib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\MXmlEPTB;Mj62NVgxOyEQvF2= MoflV2FPT0WU
RO82-W-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHCfFVKSzVyPUKuOlIxPTdizszN MUHTRW5ITVJ?
ECC10 MoLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnn2TWM2OD1{LkewNlA3KM7:TR?= NILEU4lUSU6JRWK=
MCF7 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLpNplSUUN3ME2yMlcyPDZ2IN88US=> NIHNSXVUSU6JRWK=
D-283MED MlXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTJwN{K0N{DPxE1? MV7TRW5ITVJ?
RPMI-7951 NF\mcplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fo[WlEPTB;Mj63OVY6PCEQvF2= M1O0TnNCVkeHUh?=
Ramos-2G6-4C10 M1rvO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;5TWM2OD1{Lke3NFk6KM7:TR?= MortV2FPT0WU
KGN M3PhT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFK3S45KSzVyPUKuPFE5QDRizszN NW\rSpdRW0GQR1XS
NUGC-3 M4XCRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fseWlEPTB;Mj64NlUxPSEQvF2= MWrTRW5ITVJ?
NCI-H292 MmPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWmw[mt{UUN3ME2yMlg2ODV|IN88US=> NXjkV2NXW0GQR1XS
Becker NHPiR5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7mTWM2OD1{Lkm1PFMzKM7:TR?= NYfvOGtlW0GQR1XS
NCI-H1299 M12xTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkO0TWM2OD1|LkC1NlY{KM7:TR?= NXzqOIZvW0GQR1XS
ETK-1 M1jFfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTNwMEW0N{DPxE1? MXrTRW5ITVJ?
TK10 M3za[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TRbGlEPTB;Mz6yNFE3PSEQvF2= M3K0dnNCVkeHUh?=
VMRC-RCZ MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDTcndKSzVyPUOuN|Y1QDhizszN MmLYV2FPT0WU
YH-13 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHQbIpKSzVyPUOuOFQxPzlizszN M4O4RnNCVkeHUh?=
DU-145 Mmr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTNwNE[yOlkh|ryP MoL0V2FPT0WU
SW1088 NWq2VYt6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDxTWM2OD1|LkS3OFch|ryP MXfTRW5ITVJ?
HOP-92 NEjDT2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7kTWM2OD1|LkWwN|QzKM7:TR?= NFjxdY1USU6JRWK=
KP-N-YS NEXUclJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTNwNkKxN|kh|ryP MWrTRW5ITVJ?
NCI-H460 MlPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDt[FlUUUN3ME2zMlY3PzNizszN M4nHe3NCVkeHUh?=
U-2-OS NHfBZ3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PU[GlEPTB;Mz63NlU{PSEQvF2= M3XI[3NCVkeHUh?=
A101D MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHuzU5lKSzVyPUOuO|Y6OzZizszN MnHrV2FPT0WU
MDA-MB-231 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjvRm1KSzVyPUOuPFE6PTFizszN NWDidlJFW0GQR1XS
IST-MES1 NH7LPVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULPNotlUUN3ME2zMlg{OiEQvF2= MmDIV2FPT0WU
COR-L105 NH;VXnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7Ye|ZHUUN3ME20MlAyQCEQvF2= MWLTRW5ITVJ?
NCI-H1437 MmC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3qzfWlEPTB;ND6wNlMxOiEQvF2= MnrTV2FPT0WU
CAL-85-1 NIe4NnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjz[|dKSzVyPUSuNFI1PjFizszN MV\TRW5ITVJ?
MZ1-PC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTRwMUi1OVYh|ryP NXLQ[IJjW0GQR1XS
VM-CUB-1 NG\jPJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{H6WGlEPTB;ND6zNVI5PCEQvF2= NITwVGFUSU6JRWK=
CHL-1 NVXEfo5WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTRwM{KxOlkh|ryP NHfJb4ZUSU6JRWK=
MDA-MB-361 M171UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;ZTWM2OD12LkOzNVU{KM7:TR?= NF62XnJUSU6JRWK=
NCI-H661 NIHEXWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2K2emlEPTB;ND61NFA6OiEQvF2= NFfhOYJUSU6JRWK=
EW-11 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTRwNUKyN|Eh|ryP MV\TRW5ITVJ?
BEN MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTHPGxKSzVyPUSuOVI5OTVizszN M1q3SXNCVkeHUh?=
BFTC-909 Mm\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Lq[GlEPTB;ND61OlI4PSEQvF2= MmPBV2FPT0WU
NCI-H2087 NYjWPHhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDMc|dKSzVyPUSuOVgyPjRizszN NIXyWXJUSU6JRWK=
RVH-421 Ml\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;mXXo5UUN3ME20MlY3PjlizszN NVOwUHBUW0GQR1XS
P30-OHK NFPrOlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3v5V2lEPTB;ND62PFAxQCEQvF2= MXrTRW5ITVJ?
NCI-H28 NYr2bZh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\1TWM2OD12LkixOlYyKM7:TR?= NYDGOolQW0GQR1XS
ES6 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTRwOEOwNVYh|ryP NVPVWolrW0GQR1XS
769-P MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XXW2lEPTB;ND64OVkzPiEQvF2= Mk\NV2FPT0WU
OE33 NIO3WpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTRwOEixOlEh|ryP M3excHNCVkeHUh?=
SW982 MkDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7QRXNKSzVyPUSuPVUxPjFizszN M2PUZ3NCVkeHUh?=
A388 NHLnV4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTVwMEK5PFMh|ryP MVvTRW5ITVJ?
TI-73 NFvLemVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTUTWM2OD13LkC2NVk1KM7:TR?= NFu0UmFUSU6JRWK=
HCT-116 MmrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfIRnFnUUN3ME21MlA6QDh7IN88US=> MoLaV2FPT0WU
HuP-T3 M1;ETmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHTTWM2OD13LkG4O|A6KM7:TR?= NHiwelJUSU6JRWK=
G-402 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPZTWM2OD13LkG5OFE3KM7:TR?= MUDTRW5ITVJ?
NCI-H1792 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTVwMkS2NlIh|ryP NX3SRndQW0GQR1XS
NCI-H209 M1Pu[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TaVWlEPTB;NT6yOVk1OiEQvF2= MmHRV2FPT0WU
NCI-H1650 NUGyOWtIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWG5RYZzUUN3ME21MlMxPjN2IN88US=> M{iyT3NCVkeHUh?=
LCLC-97TM1 Ml3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zIN2lEPTB;NT6zNVgxQCEQvF2= MWfTRW5ITVJ?
S-117 NWjTXG1mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTVwM{[5O|Yh|ryP NVTCZo9lW0GQR1XS
GI-ME-N NYXUemYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPi[3VKSzVyPUWuN|k3QDFizszN MoDmV2FPT0WU
NCI-H2122 NXXpUnZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\6dFVKSzVyPUWuOFk{QTdizszN M2HMNnNCVkeHUh?=
NCI-H1793 MoDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33S[2lEPTB;NT62O|U6OyEQvF2= NXz1O4ZRW0GQR1XS
C2BBe1 NFTkfYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\HdGxKSzVyPUWuO|AxQDhizszN NWfhe2xbW0GQR1XS
TE-12 Mo[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUj3SGNkUUN3ME21MlgxPTV4IN88US=> MkHWV2FPT0WU
LCLC-103H MlTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3FdIppUUN3ME21MlkyPyEQvF2= NFTtTZlUSU6JRWK=
A673 NWnk[3luT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfRb2dKSzVyPUWuPVE6OzJizszN NH36U4pUSU6JRWK=
BB30-HNC NFLpSpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTVwOUizOkDPxE1? NF\TW25USU6JRWK=
SF295 NYXMXlFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvlTWM2OD14LkCwOFIzKM7:TR?= NIXSbJlUSU6JRWK=
KU-19-19 M1u3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTZwMEG3N|Eh|ryP MV;TRW5ITVJ?
CFPAC-1 Moq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTZwMES0OFMh|ryP NX;u[ItQW0GQR1XS
LoVo NV\a[VNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUC0[VFrUUN3ME22MlA2ODZ|IN88US=> NHjGUpNUSU6JRWK=
8505C MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTZwMEe1O|Mh|ryP Mk\oV2FPT0WU
GMS-10 NXvZenE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTZwMUWwNFIh|ryP Mon4V2FPT0WU
Ca9-22 NF21fnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzZOopKSzVyPU[uNVY4OSEQvF2= MYjTRW5ITVJ?
DOK MmryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnaflljUUN3ME22MlIzODd{IN88US=> NWKxdpJqW0GQR1XS
FADU NVyyR49tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjwTWM2OD14LkK2NFM6KM7:TR?= NXn3OYpYW0GQR1XS
BxPC-3 M{W1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVG2Z4dRUUN3ME22MlI4OzJizszN MmnDV2FPT0WU
CAL-33 MofiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVq4OYNrUUN3ME22MlI6OjBzIN88US=> M{\pb3NCVkeHUh?=
SHP-77 NGjUWnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PSTGlEPTB;Nj6zNVUyOiEQvF2= MmnxV2FPT0WU
LXF-289 Mor2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPtPY1KSzVyPU[uN|M1PTVizszN MVjTRW5ITVJ?
GB-1 MmG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vldmlEPTB;Nj6zPFIh|ryP NGCzc|JUSU6JRWK=
KS-1 NVfpOXhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTZwM{i0OFch|ryP NWPQfXVqW0GQR1XS
D-502MG MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTZwNEKzO|Yh|ryP NIrUWWFUSU6JRWK=
LAN-6 NV[ybGNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HzRmlEPTB;Nj61NVAzOyEQvF2= NWnPVndXW0GQR1XS
H-EMC-SS MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUn1[W9wUUN3ME22MlU3OTR5IN88US=> NHLFUJVUSU6JRWK=
LC-2-ad NGjVVXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;TfmlEPTB;Nj62NFA4PiEQvF2= M3;KWHNCVkeHUh?=
NCI-H1693 MmPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILPN49KSzVyPU[uOlIzOTVizszN MU\TRW5ITVJ?
SK-N-FI MkPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfUdFlZUUN3ME22Mlc2ODR2IN88US=> M{fZN3NCVkeHUh?=
D-423MG M{PRTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTZwN{[xNVch|ryP NIT2WItUSU6JRWK=
KNS-42 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LndWlEPTB;Nj63PFE6PyEQvF2= M4XLfnNCVkeHUh?=
GCT NX[0U|BuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jjdWlEPTB;Nj65N|gh|ryP NYnXSm1yW0GQR1XS
DSH1 NYjNNGhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TPWGlEPTB;Nz6wOlM{KM7:TR?= MlPVV2FPT0WU
D-247MG MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHmTWM2OD15LkC3PFgyKM7:TR?= NFvFdZJUSU6JRWK=
NCI-SNU-5 M33nSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULifoFLUUN3ME23MlE5OzdzIN88US=> NVLqeXpLW0GQR1XS
TE-6 NHjwN3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nTUGlEPTB;Nz6yNFYxOSEQvF2= Mlm5V2FPT0WU
NOMO-1 M3HQe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTdwMkKxNlch|ryP MVvTRW5ITVJ?
NB17 NYjwcIFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfCT2ZKSzVyPUeuN|A{ODlizszN M{jW[HNCVkeHUh?=
EW-22 NYHhbHJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTdwM{SzOFgh|ryP NYDvc5psW0GQR1XS
EW-13 M1jHU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTdwM{WxOlIh|ryP NWLtN29vW0GQR1XS
DOHH-2 NGTzXHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HqeGlEPTB;Nz60OFAzKM7:TR?= Mn;5V2FPT0WU
TGBC1TKB Ml7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLvOFBKSzVyPUeuOFk5QTlizszN NW\WXIRjW0GQR1XS
GR-ST NGjZSoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXnRYFKSzVyPUeuOVI2QTRizszN Ml33V2FPT0WU
KYSE-520 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2e5V2lEPTB;Nz61OVUyPSEQvF2= MV;TRW5ITVJ?
CAPAN-1 MnLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTdwNUm1NUDPxE1? MnPJV2FPT0WU
HCE-4 MnznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3u1TWlEPTB;Nz62NlI4QSEQvF2= MV;TRW5ITVJ?
MLMA MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHmwZnNKSzVyPUeuOlI6PTdizszN MmLmV2FPT0WU
HT-144 MoD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIToUXFKSzVyPUeuOlU{PjhizszN MnznV2FPT0WU
KYSE-180 M4HoV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LSWGlEPTB;Nz63NVE3QSEQvF2= MU\TRW5ITVJ?
TE-5 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvnRVBKSzVyPUeuPVU6PzFizszN MWHTRW5ITVJ?
IGROV-1 NGDQRmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Px[GlEPTB;Nz65PFU2OSEQvF2= MlLrV2FPT0WU
NCI-H1581 NYjX[3lHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PObmlEPTB;OD6wNVIh|ryP MUXTRW5ITVJ?
SW1990 NGfMNJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRThwMES2OVkh|ryP NGfqOZVUSU6JRWK=
EFM-19 M3jxeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTZTWM2OD16LkC4OVQ2KM7:TR?= NF7KTFFUSU6JRWK=
OGR-1 NUjkOJZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLPbIJXUUN3ME24MlQ{ODJ|IN88US=> MYDTRW5ITVJ?
U-118-MG MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fS[WlEPTB;OD60N|Q3OyEQvF2= NYPa[41PW0GQR1XS
SK-OV-3 NHXJUHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRThwNE[3OlUh|ryP NXzVVnl4W0GQR1XS
KNS-62 NHfr[VFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rwTGlEPTB;OD61NVc3OSEQvF2= NFLKVlRUSU6JRWK=
GOTO M1vGdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXniW|E6UUN3ME24MlU4PjN3IN88US=> M37jNXNCVkeHUh?=
8305C MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGL3SJNKSzVyPUiuO|A1QDRizszN NF3xVJFUSU6JRWK=
RPMI-2650 NVnpbIdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkX1TWM2OD16LkexPVU2KM7:TR?= MVnTRW5ITVJ?
NEC8 M2LBXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfyTpRkUUN3ME24Mlc1OzB5IN88US=> NIPDVIFUSU6JRWK=
KYSE-450 Ml\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRThwOE[1OFgh|ryP MVrTRW5ITVJ?
RMG-I MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjHUFNKSzVyPUmuNVQxPThizszN NHLUcZZUSU6JRWK=
CAKI-1 NFfvVItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXyyNVVRUUN3ME25MlMyQTd7IN88US=> NIX6c4lUSU6JRWK=
KYSE-510 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3u1NGlEPTB;OT6zOVc4QCEQvF2= NWLPSI03W0GQR1XS
A4-Fuk M3PQNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MomzTWM2OD17LkO2O|AyKM7:TR?= NWLk[mFbW0GQR1XS
AN3-CA NXHmd4w4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFj3NY1KSzVyPUmuOFU1PDRizszN M2O0T3NCVkeHUh?=
SK-N-DZ NIjj[mtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XrcmlEPTB;OT63Nlg1QSEQvF2= MlzzV2FPT0WU
HSC-2 NIXvbZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LQTGlEPTB;OT63OlYzQSEQvF2= M1TWb3NCVkeHUh?=
EW-1 MnnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXXR|A1UUN3ME25Mlc6OzZ7IN88US=> NIW3UG5USU6JRWK=
D-566MG NHnYXYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknaTWM2OD17LkizOlY1KM7:TR?= MXnTRW5ITVJ?
COLO-792 NEfyb25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrNO3lJUUN3ME25Mlk5PzR4IN88US=> NGTIRZRUSU6JRWK=
TE-10 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTFyLkCzPVYh|ryP NV7vPWlHW0GQR1XS
NCI-H650 NIjFOlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TsOmlEPTB;MUCuOFI5PiEQvF2= M{X5UXNCVkeHUh?=
U-266 NVHF[ppLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVyxeYg2UUN3ME2xNE41PTVizszN MWLTRW5ITVJ?
Detroit562 NWr0U4E4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPoTWM2OD1zMT6wOVE2KM7:TR?= NGCyeoZUSU6JRWK=
NH-12 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTFzLkG0OFYh|ryP MXfTRW5ITVJ?
CO-314 NU\xN5NIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfCOG5KSzVyPUGxMlI5PDJizszN M1PHOnNCVkeHUh?=
IST-MEL1 NVTre5lNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTFzLkWzNlMh|ryP NV2wXWJJW0GQR1XS
KNS-81-FD NYHGbI51T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHryTG1KSzVyPUGxMlU2OjdizszN MWLTRW5ITVJ?
SW1463 NGPMU|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTFzLkW5PFkh|ryP M2\heXNCVkeHUh?=
NCI-H23 NH3m[2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITNXFJKSzVyPUGxMlY2PTJizszN NGG1S41USU6JRWK=
SK-MEL-2 MkntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHMNFhKSzVyPUGxMlcyQTdizszN M4n5S3NCVkeHUh?=
NB13 NHTrVFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7vSVZoUUN3ME2xNk4yPDl3IN88US=> MXTTRW5ITVJ?
Daoy M4X5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXS3WXQ6UUN3ME2xNk4zQDV4IN88US=> MXjTRW5ITVJ?
NCI-H1623 NHrjV3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7oO3pKSzVyPUGyMlM5ODFizszN MXLTRW5ITVJ?
NMC-G1 MkLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXridJIxUUN3ME2xNk44OTdizszN NUDONYd{W0GQR1XS
DK-MG NILFPYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlS4TWM2OD1zMj65OFgzKM7:TR?= NFv4PVhUSU6JRWK=
TCCSUP NFv2XXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPTTWM2OD1zMz6xNlg1KM7:TR?= M{LEXnNCVkeHUh?=
SCC-15 MmewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmq0TWM2OD1zMz6yOlUyKM7:TR?= M4XmOHNCVkeHUh?=
NOS-1 NF;vRWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXUN5JFUUN3ME2xN{4zQDl|IN88US=> MVfTRW5ITVJ?
RH-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3YTWM2OD1zMz6zNFM4KM7:TR?= NXu3UVRNW0GQR1XS
SK-MEL-3 NX\uSlV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTF|LkO3Nlgh|ryP MVPTRW5ITVJ?
NB5 NFnZbWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnUTWM2OD1zMz60NFY4KM7:TR?= M3XRWHNCVkeHUh?=
SNU-387 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\EVoRKSzVyPUGzMlUxPzJizszN MlrEV2FPT0WU
CAL-120 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIr1ZlBKSzVyPUGzMlY4OThizszN MYLTRW5ITVJ?
Mo-T MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTF|LkewO{DPxE1? Mnr2V2FPT0WU
LNCaP-Clone-FGC M1TRfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;YWmlEPTB;MUOuO|k6OiEQvF2= MYPTRW5ITVJ?
CAN NWC1SFhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXH6UZZ4UUN3ME2xOE4xOjh6IN88US=> M{O3ZXNCVkeHUh?=
SK-MEL-30 M1XDfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjUTWM2OD1zND6wOlMh|ryP Mki1V2FPT0WU
COLO-678 Mof3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVG0O4ZLUUN3ME2xOE4xQDJ{IN88US=> M{HL[XNCVkeHUh?=
SCC-9 NFvDTG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTF2LkGwNlEh|ryP NYfsdYNJW0GQR1XS
KINGS-1 MonaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXmTWM2OD1zND6xOFAzKM7:TR?= NF\6bmRUSU6JRWK=
SL-513 MmTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLWTWM2OD1zND6xPFch|ryP M{jO[HNCVkeHUh?=
HLE NGqzXWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXQTWM2OD1zND6zPFUzKM7:TR?= NGDlZlNUSU6JRWK=
SW1573 NVPoW|R3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPIT4pKSzVyPUG0MlQ1OzVizszN NETyTIxUSU6JRWK=
KYSE-140 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTF2Lk[zNlch|ryP M{PyPXNCVkeHUh?=
SK-PN-DW M1;kUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTF2LkiwNFEh|ryP NFLtZ|VUSU6JRWK=
A253 NIP1dVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTF3LkC2NlUh|ryP M1TWfHNCVkeHUh?=
CAL-12T NGf0U|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PLO2lEPTB;MUWuOFY3OiEQvF2= NXrGbI9sW0GQR1XS
COLO-679 NGryfXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnxTWM2OD1zNT63Olg{KM7:TR?= MlrZV2FPT0WU
UACC-257 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jIcGlEPTB;MU[uNVIxOSEQvF2= MXzTRW5ITVJ?
U-87-MG NYO4WXN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fBeWlEPTB;MU[uN|UzOyEQvF2= NELPcIRUSU6JRWK=
HCC1806 NYLjdYdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rwfGlEPTB;MU[uO|A4OSEQvF2= MX7TRW5ITVJ?
NCI-H2170 MkTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTF5LkK0OFgh|ryP M4njcXNCVkeHUh?=
AGS MnjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\jeVFKSzVyPUG3MlM5ODhizszN M17ndHNCVkeHUh?=
MEL-HO M3rHdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTF5Lke1NFMh|ryP Mn\KV2FPT0WU
SW48 MoPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fJS2lEPTB;MUeuO|cyPiEQvF2= MlTvV2FPT0WU
HuP-T4 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTVUVlKSzVyPUG4MlAzODZizszN NILC[5FUSU6JRWK=
NCI-H720 NFHiSJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTF6LkG0NFIh|ryP M2nPZnNCVkeHUh?=
RCC10RGB MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPwTWM2OD1zOD6xOlk4KM7:TR?= MmjQV2FPT0WU
HD-MY-Z MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{CxW2lEPTB;MUiuNlI2PCEQvF2= NWfTVGRvW0GQR1XS
A427 MlPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTtc3BKSzVyPUG4MlUxQTRizszN MlP3V2FPT0WU
HCC2998 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTF6Lk[wOVEh|ryP MULTRW5ITVJ?
EPLC-272H M3zMWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGewemNKSzVyPUG5MlA1OzRizszN M2TnRnNCVkeHUh?=
C32 MlLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3VSFBxUUN3ME2xPU4xPDVizszN M2fERnNCVkeHUh?=
UMC-11 NUW3SowyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLKNpZKSzVyPUG5MlIyOjNizszN NVjObZRFW0GQR1XS
CaR-1 NEewZYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTF7Lk[4NFQh|ryP M1PHOXNCVkeHUh?=
KYSE-410 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\EZWlnUUN3ME2xPU46OTN7IN88US=> MkXlV2FPT0WU
HuCCT1 M1\PPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\tTWM2OD1{MD62Nlk1KM7:TR?= MWHTRW5ITVJ?
LB996-RCC MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3z4NGlEPTB;MkCuO|E3QCEQvF2= MX7TRW5ITVJ?
KYSE-70 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITTNHBKSzVyPUKwMlgxPTlizszN NUnDVZhuW0GQR1XS
CAL-72 M1LuNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmW5TWM2OD1{MD65NVUh|ryP M3\JenNCVkeHUh?=
Capan-2 MojpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTJzLkC0NVMh|ryP NIS2XFZUSU6JRWK=
PANC-08-13 M3HpNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrsTWM2OD1{MT6yOVE2KM7:TR?= Mlz3V2FPT0WU
SBC-1 M16zeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITYN|hKSzVyPUKxMlMxQDFizszN NHzsc3RUSU6JRWK=
MFM-223 NYfnN3N7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPyb|dnUUN3ME2yNU4{OzR{IN88US=> MXfTRW5ITVJ?
BB49-HNC M3nJc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\6ZZRUUUN3ME2yNU42PzF4IN88US=> NGPsXm5USU6JRWK=
SH-4 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\S[2tnUUN3ME2yNU43PjF6IN88US=> NEDydWRUSU6JRWK=
HuO9 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTJzLkm4NlUh|ryP M4PLVXNCVkeHUh?=
AM-38 NHvvRldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoK2TWM2OD1{Mj6wOFg2KM7:TR?= M2rHOXNCVkeHUh?=
A431 NVe4ToxST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTJ|LkKxNVkh|ryP MnXrV2FPT0WU
YAPC M4rFO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjEfIpCUUN3ME2yN{4zPjVzIN88US=> NH;lO|lUSU6JRWK=
LU-139 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M123OGlEPTB;MkOuOFgxQSEQvF2= NXzB[mJzW0GQR1XS
HEC-1 NF7zV|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHPb3FKSzVyPUKzMlQ6OzdizszN NGK3fnVUSU6JRWK=
SCC-25 NFvscYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;TO3VKSzVyPUK0MlMxODZizszN MkHVV2FPT0WU
HT-29 NXLpXmVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFz4b5ZKSzVyPUK0MlM5OjNizszN MYjTRW5ITVJ?
PC-14 NVruR2JxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XzUWlEPTB;MkSuOlU4OSEQvF2= M2TCZnNCVkeHUh?=
Calu-6 M1TCPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTJ3LkWwO|Eh|ryP NI[3XY1USU6JRWK=
SJRH30 NFfKUnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXmTWM2OD1{NT62OFk3KM7:TR?= MYrTRW5ITVJ?
ChaGo-K-1 M{\jdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTVTWM2OD1{Nj6xOlI6KM7:TR?= NFTuOVJUSU6JRWK=
IA-LM Ml7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjBN5FKSzVyPUK2MlM3PDVizszN M3rtWXNCVkeHUh?=
GP5d NVnBOml[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzpTFl2UUN3ME2yOk41PDlzIN88US=> NHKwR5BUSU6JRWK=
NCI-H2291 MoT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TMemlEPTB;Mk[uOlU1OSEQvF2= NHLkXG9USU6JRWK=
BALL-1 NIjkU2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DJNmlEPTB;Mk[uPVM6PyEQvF2= M4\LWXNCVkeHUh?=
HCC1954 Moe3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlj0TWM2OD1{Nj65PFA5KM7:TR?= NGCyR3JUSU6JRWK=
NCI-H2452 NWTOR3FpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTJ5LkSxOlMh|ryP M3XrbHNCVkeHUh?=
LU-99A NHPtTZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{G3[2lEPTB;MkeuOVU5OiEQvF2= M4ruPXNCVkeHUh?=
NTERA-S-cl-D1 M3;Le2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTJ5LkeyPVkh|ryP NHXYUoxUSU6JRWK=
PANC-10-05 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPBTWM2OD1{Nz63O|c2KM7:TR?= M4PoS3NCVkeHUh?=
NCI-H2405 MnzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzhTWM2OD1{Nz65N|g4KM7:TR?= NWXOdXl2W0GQR1XS
MDA-MB-415 M1PDd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\uZWlEPTB;MkiuOFE{PyEQvF2= Ml\NV2FPT0WU
NCI-H2342 NVHiR|ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPYU|V4UUN3ME2yPE42OjhzIN88US=> NFPiNmZUSU6JRWK=
TGBC24TKB NVy4O2ZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLhNJpKSzVyPUK4MlcyOTdizszN MV3TRW5ITVJ?
LU-134-A MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnqN4JEUUN3ME2yPE46OjZzIN88US=> NWfwOXdYW0GQR1XS
SCC-4 NUfiTnNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fW[2lEPTB;M{GuNFQ6PCEQvF2= NUHJbXdKW0GQR1XS
Saos-2 MmPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLFTWM2OD1|MT65N|A3KM7:TR?= NFzFOYVUSU6JRWK=
RERF-LC-MS MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTN{LkiyN|Eh|ryP Mo\aV2FPT0WU
M14 M4nQfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXvNnhKSzVyPUOyMlk4PjRizszN NWfuW3hLW0GQR1XS
HPAF-II NWn5SIRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTN|LkWwNVEh|ryP NH63XIVUSU6JRWK=
NCI-H1755 MlTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TSd2lEPTB;M{SuN|MxPSEQvF2= NHfJPZlUSU6JRWK=
D-392MG MofHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTvW3JKSzVyPUO1Mlg3PzRizszN Mn\HV2FPT0WU
A704 M4H6fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHryd4xKSzVyPUO2MlA1OjdizszN MmLWV2FPT0WU
CP50-MEL-B Mn;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1foV2lEPTB;M{[uNVkyOSEQvF2= MXLTRW5ITVJ?
EW-18 NHL4cINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmriTWM2OD1|Nj60OVIh|ryP NF3HOZlUSU6JRWK=
WM-115 M3PzeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2iyOmlEPTB;M{[uPFA6QSEQvF2= NVnBSox[W0GQR1XS
LU-65 NW\UVmZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;YcWlEPTB;M{euNVQyPyEQvF2= MlThV2FPT0WU
NCI-H1563 MlPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDSe4MxUUN3ME2zO{4zPDh2IN88US=> MULTRW5ITVJ?
DBTRG-05MG MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnRPJFUUUN3ME2zPE4xPjlzIN88US=> MU\TRW5ITVJ?
NCI-H630 MoT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnu0TWM2OD1|OD60O|E1KM7:TR?= NY\UZ5ZwW0GQR1XS
NCI-H1155 NILt[4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzmVndKSzVyPUO5MlI1OiEQvF2= NGm2PWhUSU6JRWK=
OVACR-3 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\2OmlEPTB;M{muPVE6PSEQvF2= MXHTRW5ITVJ?
OAW-42 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljlTWM2OD12MD60NlU5KM7:TR?= MXHTRW5ITVJ?
JVM-2 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\pe3FKSzVyPUSxMlI1OTVizszN NXLMdHFRW0GQR1XS
C3A NXLpU2R1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LCPWlEPTB;NEGuN|Q1PyEQvF2= MWfTRW5ITVJ?
HT55 NF7kbZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXP5WWp{UUN3ME20Nk4zQDRzIN88US=> MWXTRW5ITVJ?
OVCAR-4 MoHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTvbm1KSzVyPUSyMlI6PzRizszN NH76XlNUSU6JRWK=
MEG-01 M17rfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfCZoo{UUN3ME20Nk41PjF4IN88US=> NHHOXnNUSU6JRWK=
NCI-H82 M2LDTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjzTVdKSzVyPUSzMlk5QTJizszN NFS3UlBUSU6JRWK=
JEG-3 MmT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWX0XHJlUUN3ME20OE46PDdizszN NUfxcmRHW0GQR1XS
BPH-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlraTWM2OD12Nj6zPVk5KM7:TR?= MYjTRW5ITVJ?
MPP-89 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofiTWM2OD12Nz6yPFk5KM7:TR?= MXnTRW5ITVJ?
ALL-PO NELKN|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PMbmlEPTB;NEeuOFE5QCEQvF2= M2W5dnNCVkeHUh?=
HT MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrYXWJKSzVyPUS3MlQ6OiEQvF2= MojaV2FPT0WU
NCI-H2347 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTR6LkC3NVUh|ryP M1T1PHNCVkeHUh?=
A2780 NH7DVIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PoemlEPTB;NEmuOFIzQCEQvF2= M3XmZnNCVkeHUh?=
KARPAS-299 MnXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfTZYZKSzVyPUS5MlUyOTlizszN NGTYbWRUSU6JRWK=
NCI-H1651 M3jTZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIO2bphKSzVyPUS5Mlg5OjFizszN NGn4WVZUSU6JRWK=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. [1]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Cdk Assays:

A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-32P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-32P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-32P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4  °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
細胞試験:

[1]

+ 展開
  • 細胞株: Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562
  • 濃度: 0.01-1 μM
  • 反応時間: 24 hours
  • 実験の流れ:

    Cells are seeded at 2 × 104 per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [14C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice.
  • 製剤: Dissolved in sodium lactate buffer (50 mM, pH 4.0)
  • 投薬量: 0-150 mg/kg
  • 投与方法: Given by gavage
    (参考用のみ)

溶解度 (25°C)

体外 Water 30 mg/mL (61.98 mM)
DMSO 3 mg/mL warmed (6.19 mM)
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
Saline
混合させたのち直ちに使用することを推奨します。
6 mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 483.99
化学式

C24H29N7O2.HCl

CAS No. 827022-32-2
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03472573 Recruiting Recurrent B Acute Lymphoblastic Leukemia|Refractory B Acute Lymphoblastic Leukemia Sidney Kimmel Cancer Center at Thomas Jefferson University|Pfizer|Thomas Jefferson University May 9 2018 Phase 1
NCT03423199 Recruiting Breast Neoplasms National Cancer Center Japan|Pfizer|Korean Cancer Study Group February 9 2018 Phase 3
NCT03147287 Recruiting Metastatic Breast Cancer Dana-Farber Cancer Institute|Pfizer August 9 2017 Phase 2
NCT02905318 Recruiting Prostate Cancer Canadian Cancer Trials Group|Pfizer February 9 2017 Phase 2
NCT02679755 Recruiting Breast Cancer Pfizer March 9 2016 Phase 4
NCT03284957 Recruiting Breast Cancer Sanofi September 8 2017 Phase 1|Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

CDKシグナル伝達経路

CDK Inhibitors with Unique Features

相関CDK製品

Tags: Palbociclib (PD-0332991) HClを買う | Palbociclib (PD-0332991) HCl ic50 | Palbociclib (PD-0332991) HCl供給者 | Palbociclib (PD-0332991) HClを購入する | Palbociclib (PD-0332991) HCl費用 | Palbociclib (PD-0332991) HCl生産者 | オーダーPalbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl化学構造 | Palbociclib (PD-0332991) HCl分子量 | Palbociclib (PD-0332991) HCl代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID